Is there a place for combination medical therapy?

Area of Science:

• Urology
• Pharmacology
• Medical Therapy

Background:

• Alpha adrenergic receptor blockers and 5alpha-reductase inhibitors are common medical treatments for lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).
• These drug classes have demonstrated individual efficacy and safety in numerous clinical trials.
• Combining these therapies is theoretically promising due to different mechanisms of action.

Purpose of the Study:

• To evaluate the efficacy and safety of combination medical therapy for LUTS and BPH.
• To review available evidence on combination therapy versus monotherapy or placebo.
• To identify gaps in knowledge regarding combination therapy for BPH.

Main Methods:

• Review of prospective, randomized, placebo-controlled studies.
• Analysis of data from trials comparing alpha blocker-finasteride combination therapy with placebo.
• Consideration of evidence from less well-controlled studies.

Main Results:

• Two large, well-conducted trials did not show superior efficacy for the combination therapy compared to placebo.
• Some less rigorously designed studies suggested potential benefits of combination therapy.
• Finasteride shows promise in men with larger prostates and higher PSA levels.

Conclusions:

• Current high-quality evidence does not support superior efficacy of alpha blocker-finasteride combination therapy for LUTS/BPH.
• Further well-designed trials are needed, particularly in specific patient populations like those with large glands.
• Investigating combination therapy in men with higher PSA levels may yield valuable insights.